haloprotac3 Search Results


haloprotac3  (MedChemExpress)
94
MedChemExpress haloprotac3
Haloprotac3, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/haloprotac3/product/MedChemExpress
Average 94 stars, based on 1 article reviews
haloprotac3 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
haloprotac3  (Promega)
90
Promega haloprotac3
a Comparison of expression levels for XPR1 degron fusion proteins in various cell lines. Expression was determined by quantifying the western blot V5 band intensity and normalizing it to a Vinculin loading control. b Phosphate efflux activity of XPR1 degron fusion proteins. 293T cells endogenously express XPR1, which was inactivated using CRISPR/Cas9 (XPR1-KO) followed by re-expression of wild-type XPR1 (WT), a hypomorphic allele (L218S), or the indicated SFFV-driven degron fusion proteins. Three days after the addition of degrader drug (1 μM Pomalidomide, 1 μM dTAG V −1, or 1 μM <t>HaloPROTAC3),</t> phosphate efflux was measured by “loading cells” for 45 min with 32 PO 4 3− , washing away any extracellular 32 P, and then incubating the cells for 60 min and measuring the percentage of 32 P in the conditioned medium compared to cellular lysates. The bar height represents the mean of technical triplicates (shown as points), and the results are representative of two independent experiments. c MCL1-CDT fusions are expressed and degraded in A375 cells. Cells expressing the indicated MCL1-CDT proteins were treated with 1 μM Asunaprevir or 1 μM dTAG V −1 prior to evaluating protein levels by western blot. d Evaluation of MCL1 degron fusions to protect cells from Navitoclax-induced cell death. Endogenous MCL1 was inactivated in A375 cells expressing the MCL1-CDT fusions shown in c and then pretreated with the indicated degrader drugs for 5 days (Asunaprevir) or 1 day (dTAG V −1). At “time 0”, the cells were treated with 625 nM Navitoclax and cell growth was evaluated with live-cell imaging, and confluency was evaluated through image analysis. Error bars represent the mean of N = 3 technical replicates and are representative of N = 2 independent experiments.
Haloprotac3, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/haloprotac3/product/Promega
Average 90 stars, based on 1 article reviews
haloprotac3 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
haloprotac3 aob36136  (Aobious Inc)
90
Aobious Inc haloprotac3 aob36136
a Comparison of expression levels for XPR1 degron fusion proteins in various cell lines. Expression was determined by quantifying the western blot V5 band intensity and normalizing it to a Vinculin loading control. b Phosphate efflux activity of XPR1 degron fusion proteins. 293T cells endogenously express XPR1, which was inactivated using CRISPR/Cas9 (XPR1-KO) followed by re-expression of wild-type XPR1 (WT), a hypomorphic allele (L218S), or the indicated SFFV-driven degron fusion proteins. Three days after the addition of degrader drug (1 μM Pomalidomide, 1 μM dTAG V −1, or 1 μM <t>HaloPROTAC3),</t> phosphate efflux was measured by “loading cells” for 45 min with 32 PO 4 3− , washing away any extracellular 32 P, and then incubating the cells for 60 min and measuring the percentage of 32 P in the conditioned medium compared to cellular lysates. The bar height represents the mean of technical triplicates (shown as points), and the results are representative of two independent experiments. c MCL1-CDT fusions are expressed and degraded in A375 cells. Cells expressing the indicated MCL1-CDT proteins were treated with 1 μM Asunaprevir or 1 μM dTAG V −1 prior to evaluating protein levels by western blot. d Evaluation of MCL1 degron fusions to protect cells from Navitoclax-induced cell death. Endogenous MCL1 was inactivated in A375 cells expressing the MCL1-CDT fusions shown in c and then pretreated with the indicated degrader drugs for 5 days (Asunaprevir) or 1 day (dTAG V −1). At “time 0”, the cells were treated with 625 nM Navitoclax and cell growth was evaluated with live-cell imaging, and confluency was evaluated through image analysis. Error bars represent the mean of N = 3 technical replicates and are representative of N = 2 independent experiments.
Haloprotac3 Aob36136, supplied by Aobious Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/haloprotac3 aob36136/product/Aobious Inc
Average 90 stars, based on 1 article reviews
haloprotac3 aob36136 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
haloprotac3-mediated degradation assay in primary human hepatocytes  (BioIVT Inc)
90
BioIVT Inc haloprotac3-mediated degradation assay in primary human hepatocytes
a Comparison of expression levels for XPR1 degron fusion proteins in various cell lines. Expression was determined by quantifying the western blot V5 band intensity and normalizing it to a Vinculin loading control. b Phosphate efflux activity of XPR1 degron fusion proteins. 293T cells endogenously express XPR1, which was inactivated using CRISPR/Cas9 (XPR1-KO) followed by re-expression of wild-type XPR1 (WT), a hypomorphic allele (L218S), or the indicated SFFV-driven degron fusion proteins. Three days after the addition of degrader drug (1 μM Pomalidomide, 1 μM dTAG V −1, or 1 μM <t>HaloPROTAC3),</t> phosphate efflux was measured by “loading cells” for 45 min with 32 PO 4 3− , washing away any extracellular 32 P, and then incubating the cells for 60 min and measuring the percentage of 32 P in the conditioned medium compared to cellular lysates. The bar height represents the mean of technical triplicates (shown as points), and the results are representative of two independent experiments. c MCL1-CDT fusions are expressed and degraded in A375 cells. Cells expressing the indicated MCL1-CDT proteins were treated with 1 μM Asunaprevir or 1 μM dTAG V −1 prior to evaluating protein levels by western blot. d Evaluation of MCL1 degron fusions to protect cells from Navitoclax-induced cell death. Endogenous MCL1 was inactivated in A375 cells expressing the MCL1-CDT fusions shown in c and then pretreated with the indicated degrader drugs for 5 days (Asunaprevir) or 1 day (dTAG V −1). At “time 0”, the cells were treated with 625 nM Navitoclax and cell growth was evaluated with live-cell imaging, and confluency was evaluated through image analysis. Error bars represent the mean of N = 3 technical replicates and are representative of N = 2 independent experiments.
Haloprotac3 Mediated Degradation Assay In Primary Human Hepatocytes, supplied by BioIVT Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/haloprotac3-mediated degradation assay in primary human hepatocytes/product/BioIVT Inc
Average 90 stars, based on 1 article reviews
haloprotac3-mediated degradation assay in primary human hepatocytes - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier
haloprotac3  (Biosynth Carbosynth)
N/A
   Buy from Supplier
haloprotac3  (TargetMol)
N/A
   Buy from Supplier

Image Search Results


a Comparison of expression levels for XPR1 degron fusion proteins in various cell lines. Expression was determined by quantifying the western blot V5 band intensity and normalizing it to a Vinculin loading control. b Phosphate efflux activity of XPR1 degron fusion proteins. 293T cells endogenously express XPR1, which was inactivated using CRISPR/Cas9 (XPR1-KO) followed by re-expression of wild-type XPR1 (WT), a hypomorphic allele (L218S), or the indicated SFFV-driven degron fusion proteins. Three days after the addition of degrader drug (1 μM Pomalidomide, 1 μM dTAG V −1, or 1 μM HaloPROTAC3), phosphate efflux was measured by “loading cells” for 45 min with 32 PO 4 3− , washing away any extracellular 32 P, and then incubating the cells for 60 min and measuring the percentage of 32 P in the conditioned medium compared to cellular lysates. The bar height represents the mean of technical triplicates (shown as points), and the results are representative of two independent experiments. c MCL1-CDT fusions are expressed and degraded in A375 cells. Cells expressing the indicated MCL1-CDT proteins were treated with 1 μM Asunaprevir or 1 μM dTAG V −1 prior to evaluating protein levels by western blot. d Evaluation of MCL1 degron fusions to protect cells from Navitoclax-induced cell death. Endogenous MCL1 was inactivated in A375 cells expressing the MCL1-CDT fusions shown in c and then pretreated with the indicated degrader drugs for 5 days (Asunaprevir) or 1 day (dTAG V −1). At “time 0”, the cells were treated with 625 nM Navitoclax and cell growth was evaluated with live-cell imaging, and confluency was evaluated through image analysis. Error bars represent the mean of N = 3 technical replicates and are representative of N = 2 independent experiments.

Journal: Nature Communications

Article Title: Systematic profiling of conditional degron tag technologies for target validation studies

doi: 10.1038/s41467-022-33246-4

Figure Lengend Snippet: a Comparison of expression levels for XPR1 degron fusion proteins in various cell lines. Expression was determined by quantifying the western blot V5 band intensity and normalizing it to a Vinculin loading control. b Phosphate efflux activity of XPR1 degron fusion proteins. 293T cells endogenously express XPR1, which was inactivated using CRISPR/Cas9 (XPR1-KO) followed by re-expression of wild-type XPR1 (WT), a hypomorphic allele (L218S), or the indicated SFFV-driven degron fusion proteins. Three days after the addition of degrader drug (1 μM Pomalidomide, 1 μM dTAG V −1, or 1 μM HaloPROTAC3), phosphate efflux was measured by “loading cells” for 45 min with 32 PO 4 3− , washing away any extracellular 32 P, and then incubating the cells for 60 min and measuring the percentage of 32 P in the conditioned medium compared to cellular lysates. The bar height represents the mean of technical triplicates (shown as points), and the results are representative of two independent experiments. c MCL1-CDT fusions are expressed and degraded in A375 cells. Cells expressing the indicated MCL1-CDT proteins were treated with 1 μM Asunaprevir or 1 μM dTAG V −1 prior to evaluating protein levels by western blot. d Evaluation of MCL1 degron fusions to protect cells from Navitoclax-induced cell death. Endogenous MCL1 was inactivated in A375 cells expressing the MCL1-CDT fusions shown in c and then pretreated with the indicated degrader drugs for 5 days (Asunaprevir) or 1 day (dTAG V −1). At “time 0”, the cells were treated with 625 nM Navitoclax and cell growth was evaluated with live-cell imaging, and confluency was evaluated through image analysis. Error bars represent the mean of N = 3 technical replicates and are representative of N = 2 independent experiments.

Article Snippet: HaloPROTAC3 , Promega , CS2072A01.

Techniques: Expressing, Western Blot, Activity Assay, CRISPR, Live Cell Imaging

Compounds used in this study

Journal: Nature Communications

Article Title: Systematic profiling of conditional degron tag technologies for target validation studies

doi: 10.1038/s41467-022-33246-4

Figure Lengend Snippet: Compounds used in this study

Article Snippet: HaloPROTAC3 , Promega , CS2072A01.

Techniques: